BLIV + Insulin IQ Metabolic Health Support Program

Your medication is only part of the plan.

Your GLP-1-based medication can be a powerful tool. But medication is only one part of improving your metabolic health.

That’s why your BLIV care includes access to the BLIV + Insulin IQ Metabolic Health Support Program—an integrated program of metabolic health education, personalized AI guidance, and ongoing live support designed specifically for people using GLP-1-based medications.

Built on the research and teaching of Dr. Ben Bikman

More Than a Prescription

GLP-1-based medications can help reduce hunger, cravings, and “food noise”—creating an opportunity to make changes that may have been difficult before.

But medication can't teach you what to eat, how to protect muscle, why insulin resistance matters, what to do when challenges arise, or how to build healthier habits that can last.

That's where your Insulin IQ support comes in.

You don't have to figure everything out on your own. Your BLIV care gives you three complementary kinds of support designed to work together throughout your GLP-1 journey:

Learn. Ask. Connect.

Why Dr. Ben Bikman’s Thinking on GLP-1-Based Medications Has Evolved

If you’ve followed Ben or Insulin IQ for very long, you may have noticed something: Dr. Bikman’s position on GLP-1–based medications has changed. That isn’t your imagination.

For years, Ben was highly skeptical of medications such as semaglutide and other GLP-1-based drugs. More recently, however, he has begun talking about them differently. He now believes, based on continued research and emerging science, that these medications can have an appropriate and potentially valuable role in improving metabolic health.

For some longtime followers, that change has been confusing and has raised questions. We want to address those questions directly.

Ben’s evolving view is about more than simply becoming more accepting of GLP-1-based medications. As the research has developed, so has his thinking about how these medications should be used—not simply as weight-loss drugs, but as tools that, when used thoughtfully, may help create an opportunity to improve metabolic health and establish changes that can last beyond the medication itself.

That distinction—and the things that have not changed in Ben’s thinking—matter.

Following the Data—Wherever It Leads

Ben has often said that one of the most important responsibilities of a scientist is to “follow the data”. That sounds simple, but sometimes following the data means arriving at a different conclusion than the one you held before. That is exactly what has been happening with Ben’s thinking about GLP-1-based medications.

The following is a 7-minute excerpt from 1-hour interview Ben did in August, 2026 with Dominic D’Agostino, PhD, and co-host Victoria Field for the 100th episode of The Metabolic Link:

As a Reminder... You can use the “speedometer” icon at the bottom of the video to watch at various speeds.

The Study Dr. Bikman Refers To

Ben refers to a newly released study led by himself and the team at Summit Family Health & Metabolic Clinic, including Insulin IQ’s Coaching Director, Carlie Wendel, and Insulin IQ’s Medical Advisor, Bill Jensen PA-C, MMS. The study examines the combination of a whole-food ketogenic diet, personalized coaching, and low-dose semaglutide (Ozempic/Wegovy). In this small six-month case series, participants lost an average of nearly 48 pounds, with about 92% of the weight loss coming from body fat rather than muscle, while also improving several key markers of metabolic health. Although the results are promising, Ben emphasizes that larger, randomized clinical trials are needed to confirm these preliminary findings.

Ben said, “The paper published this week looked at the use of low dose GLP-1 drugs when combined with coaching, and low-carb, ketogenic diets. The results were just phenomenal. People were able to stay at very low doses and have substantially greater fat loss than when it was just the drug alone.”

You can download the full study by clicking the image below:

Science is not static.

New studies are published. Better data become available. Earlier findings are reexamined. And sometimes a concern that once seemed compelling looks different as our understanding becomes more complete and nuanced.

For Ben, following the data means not defending something he said—even if said fairly recently—simply because he said it. It means continuing to ask what the evidence shows now—even when the answer leads somewhere he did not initially expect to go.

Today, Ben says plainly, “I think there’s absolutely a place for these drugs.”

But understanding what he means by that is critical.

Additional Recent Studies, Lectures & Reviews

Dr. Bikman’s Research Review #75: Do GLP-1 Drugs Destroy Muscle? The Truth May Be Different (May 4, 2026)

Dr. Bikman reviews a 2026 study challenging concerns that GLP-1 drugs cause significant muscle loss, finding that they primarily reduce fat while largely preserving muscle strength, endurance, and function.

Reference: https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00082-0

Research Review #75
Do GLP-1-Based Drugs Destroy Muscle? The Truth May Be Different
8:06
 

Dr. Bikman’s Research Review #81: GLP-1 Medications and the Psychology of Lasting Change (Jun 15, 2026)

Ben reviews a 2026 paper suggesting that GLP-1 medications can create a temporary window of reduced cravings that should be used to build lasting behavioral and lifestyle habits that can persist after the medication is discontinued.

Reference: https://link.springer.com/article/10.1007/s11154-026-10047-4

Research Review #81
GLP-1-Based Medications and the Psychology of Lasting Change
9:26
 

Dr. Bikman’s Research Review #84: The Lowest Effective Dose of GLP-1 Therapy (Jul 8, 2026)

Dr. Bikman reviews a 2026 study suggesting that individualized, lower-dose semaglutide may produce substantial weight loss while improving tolerability and reducing the need for automatic escalation to the highest approved dose.

Reference: https://www.nature.com/articles/s41598-026-56147-8

Research Review #84
The Lowest Effective Dose of GLP-1 Therapy
6:48
 

Dr. Bikman’s Research Review #88: What Tirzepatide Reveals About Type 1 Diabetes (Aug 10, 2026)

This 2026 real-world study found that low-dose tirzepatide in adults with type 1 diabetes and obesity produced substantial weight loss, improved blood sugar and cardiovascular markers, and reduced daily insulin requirements by 27%—highlighting insulin resistance as an important and treatable feature of type 1 diabetes.

Reference: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.71080

Research Review #88
What Tirzepatide Reveals About Type 1 Diabetes
7:10
 

Why Tirzepatide Works Better Than GLP-1 Alone (May 18, 2026)

Tirzepatide activates both GLP-1 and GIP receptors, producing weight loss primarily through appetite suppression, slower gastric emptying, reduced cravings, and improved insulin sensitivity—not by forcing the pancreas to make more insulin. Dr. Bikman argues that its best use may be as a temporary tool to help people regain control of food choices and lower the insulin-driving habits that caused metabolic dysfunction.

Why Retatrutide May Outperform GLP-1 Drugs (May 25, 2026)

Retatrutide activates GLP-1, GIP, and glucagon receptors, combining appetite suppression with increased energy expenditure and powerful liver fat reduction. Dr. Bikman argues that its best use is not as a permanent shortcut, but as a tool to help people regain control over food habits and eventually reduce reliance on medication.

Why Amylin May Be the Most Important Weight Loss Hormone You've Never Heard Of (June 8, 2026)

Amylin is an insulin-sparing satiety hormone released with insulin that slows digestion, restrains glucagon, and helps reduce post-meal glucose spikes. New amylin-based therapies, especially when combined with GLP-1 drugs, may offer powerful weight-loss effects by restoring natural fullness signals rather than forcing insulin higher.

The Drugs Aren’t the Only Issue. The Doses Matter.

This is an important distinction because Ben has not simply embraced the conventional way these medications are often prescribed.

In many treatment protocols, patients begin at a standardized dose and are then moved progressively toward larger doses. Ben has consistently questioned the idea that more medication is automatically better.

His preference is much more cautious: use the lowest effective dose, increase only when there is a good reason to do so, and be patient. In many cases, that can mean what is commonly called “microdosing.”

The goal should not be to suppress appetite so dramatically that a person can barely eat. It should be to use only as much medication as necessary to provide metabolic benefit while still allowing adequate nutrition—especially protein—and preserving muscle.

A Medication Is Not a Metabolic-Health Strategy

This may be the most important thing that has not changed in Ben’s thinking.

Insulin resistance still matters. Food quality still matters. Adequate protein still matters. Resistance training and preserving muscle still matter. Sleep, activity, and the behaviors that determine long-term metabolic health still matter.

What has become clearer is the role a GLP-1-based medication might play within that larger strategy.

Ben increasingly sees these medications as tools that can reduce hunger, cravings, and what is sometimes called “food noise,” creating a window in which it may be easier for someone to improve nutrition, protect and build muscle, improve insulin sensitivity, and establish healthier habits.

That is also why Ben does not believe the objective should automatically be to keep increasing the dose—or necessarily to remain on the medication indefinitely. His emerging approach emphasizes using the lowest effective dose, protecting lean mass, and, when appropriate, gradually reducing medication exposure as metabolic health and behavioral habits improve.

For some people, a small maintenance dose may still be appropriate. For others, the ultimate goal may be to discontinue the medication under medical supervision.

The important point is that the medication is a tool within the metabolic-health strategy. It is not the strategy itself.

Insulin IQ® Is Evolving, Too

As Ben’s thinking about GLP-1-based medications has evolved, Insulin IQ has been evolving with him. More and more people in our community are already using these medications—or considering them. Rather than simply debating whether GLP-1s are “good” or “bad,” we believe the more useful question is how someone who chooses to use them can do so in a way that supports long-term metabolic health.

That is why Insulin IQ has begun holding regular live meetups specifically focused on “Using GLP-1 Medications Wisely: An Insulin-Smart, Metabolic Health Approach.”

These sessions are not about promoting GLP-1 medications. They are about helping people understand how these drugs fit—or sometimes do not fit—within the metabolic-health principles Ben and Insulin IQ have taught for years.

That means asking questions that go far beyond weight loss:

  • How can someone improve nutrition while using the medication? How can muscle be protected?
  • How can insulin resistance and overall metabolic health improve?
  • Can lower doses accomplish the desired goal?
  • Can the period of reduced appetite and cravings be used to establish habits that may ultimately reduce dependence on the medication?

In other words, Insulin IQ is following Ben’s lead by moving beyond the simple question of whether GLP-1 medications should be used and focusing instead on how they can be used wisely.

The fundamental mission has not changed. Insulin IQ remains focused on education and coaching—providing the “off ramp”, helping people understand their metabolism, and giving them the knowledge and tools to make better decisions about their health.

Insulin IQ® Is Evolving, Too

As Ben’s thinking about GLP-1-based medications has evolved, Insulin IQ has been evolving with him. More and more people in our community are already using these medications—or considering them. Rather than simply debating whether GLP-1s are “good” or “bad,” we believe the more useful question is how someone who chooses to use them can do so in a way that supports long-term metabolic health.

That is why Insulin IQ has begun holding regular live meetups specifically focused on “Using GLP-1 Medications Wisely: An Insulin-Smart, Metabolic Health Approach.”

These sessions are not about promoting GLP-1 medications. They are about helping people understand how these drugs fit—or sometimes do not fit—within the metabolic-health principles Ben and Insulin IQ have taught for years.

That means asking questions that go far beyond weight loss:

  • How can someone improve nutrition while using the medication? How can muscle be protected?
  • How can insulin resistance and overall metabolic health improve?
  • Can lower doses accomplish the desired goal?
  • Can the period of reduced appetite and cravings be used to establish habits that may ultimately reduce dependence on the medication?

In other words, Insulin IQ is following Ben’s lead by moving beyond the simple question of whether GLP-1 medications should be used and focusing instead on how they can be used wisely.

The fundamental mission has not changed. Insulin IQ remains focused on education and coaching—providing the “off ramp”, helping people understand their metabolism, and giving them the knowledge and tools to make better decisions about their health.

Dr. Bikman’s Relationship With Metabody

Ben now serves as Chief Science Officer for Metabody. Metabody is building an integrated metabolic-health platform designed to provide continuous care rather than episodic doctor visits. It brings together wearable data, labs, medical records, clinical-grade AI, telehealth, prescribing, and eventually in-person clinics so that health signals can be continuously interpreted and acted upon by licensed clinicians. The company is using GLP-1-based care as its initial entry point, with an emphasis on protecting lean mass, improving body composition, and ultimately helping patients maintain results rather than simply remaining on medication indefinitely. Metabody already has a nationwide provider network, approximately 5,000 active members and more than 20,000 patients served. Its long-term vision is a single closed-loop system that continuously turns an individual’s health data into personalized interpretation, clinical action, and measurable outcomes.

Recently, Metabody acquired Bliv, a medical platform that provides GLP-1-based treatment. Ben’s involvement with Bliv exists through that acquisition and his broader role at Metabody. Shortly, Bliv—as a separate entity—will not exist but will become part of the Metabody platform.

It is understandable that the timing might cause some people to wonder whether Ben’s changing perspective on GLP-1-based medications is connected to his involvement with Metabody. But the reality is much more nuanced. Ben had already been discussing ideas with Metabody founder Craig Weston about more thoughtful ways to use GLP-1-based medications—including the possibility of using them in lower-dose “cycles”—well before Metabody acquired Bliv.

For Ben, the larger opportunity with Metabody is not simply about GLP-1-based medications. It is the opportunity to help influence how metabolic healthcare itself evolves.

After spending much of his career studying what is wrong with the way metabolic disease is understood and treated, Ben now has an opportunity to help build something better.

That distinction also helps clarify the different roles of Insulin IQ and Metabody.

Insulin IQ is fundamentally an education platform. Its purpose is to help people understand insulin resistance, nutrition, exercise, metabolic health, and increasingly, how medications such as GLP-1s can be used in an insulin-smart way.

Metabody is building a medical platform. That means putting many of those ideas into the healthcare environment, where clinicians, technology, data, lifestyle interventions, and medications can all be part of the care someone receives.

These are not competing philosophies. In fact, Ben hopes they will increasingly complement one another. And when GLP-1-based medications are part of that medical care, Ben wants to help move the conversation beyond simply prescribing a drug and increasing the dose. His interest remains in how these medications can be used more thoughtfully—alongside nutrition, behavior change, muscle preservation, and the larger goal of improving metabolic health.

So, Has Ben Changed His Mind?

Yes. The evidence changed his view of where GLP-1-based medications may have a legitimate role.

But perhaps the more important evolution is that Ben has developed a clearer view of how these medications can be used wisely.

His emerging approach is not simply to prescribe a drug, continually increase the dose, and measure success by pounds lost. It is to use medication thoughtfully and at the lowest effective dose, while addressing insulin resistance, nutrition, muscle, exercise, and the behaviors necessary for lasting metabolic health—with the goal of reducing reliance on the medication when appropriate.

In that sense, the fundamental principles that have defined Ben’s work for years have not changed. The goal is still better metabolic health—not simply a lower number on the scale.

What has changed is Ben’s understanding of how GLP-1-based medications may sometimes help people get there.

The information on this website is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of qualified health providers with questions you may have regarding medical conditions.